Maximize the Clinical Potential of Your Antibody-Drug Conjugate at the virtual World ADC Asia Summit

The 3^rd World ADC Asia is is going virtual for  the first time, as the only meeting focused on antibody-drug conjugate development, bringing together key opinion leaders from the pioneering companies in Asia and the rest of the world including Miracogen, Daiichi Sankyo and Astellas

Across 2 days, this comprehensive antibody-drug conjugate conference will enable you to propel your ADC pipeline into clinical development. Some of the highlights from the 2020 meeting include exploring targets beyond HER-2; confidently meeting Chinese NMPA regulatory requirements to successfully translate into the clinic and effectively scaling up your manufacturing processes for clinical development. World ADC Asia not only delves into general antibody-drug conjugate challenges, it also focuses on challenges and opportunities specific to development within Asia.

Use this opportunity to network with potential collaborators, foster new connections and further cement existing partnerships.